Skip to main content
  • Donate Blood (Opens in a new tab/window)
  • About NBA
  • News and updates
  • Resources
  • BloodPortal login (Opens in a new tab/window)
Logo image Logo image
  • Blood Products
    • Blood Products
    • National Product Price List
    • Fresh Blood Products
    • Albumin Products
    • Clotting Factor and Other Products
    • Immunoglobulin Products
      • Immunoglobulin Usage and Data
      • Intravenous Immunoglobulin (IVIg)
      • Subcutaneous Immunoglobulin (SCIg)
      • Normal Human Immunoglobulin (NHIg)
      • Hyperimmune Immunoglobulin Products
    • Access and Ordering
      • BloodSTAR for Ig Products
      • BloodSTAR Registration Form
      • BloodNet for Blood Products from Lifeblood
      • BloodNet System Interface
      • Frequently Asked Questions
    • Blood Product Management
      • Inventory Management
      • Blood Product Wastage
      • Blood and Inventory Management Resources
      • Case Studies
      • Single Unit Transfusion Guide
  • Supply System
    • Supply System
    • Managing Blood Supply
      • Risk Management
      • National Stewardship Program
      • Blood Product Labelling
    • Governance for Immunoglobulin Products
      • National Immunoglobulin Governance Committees
      • Criteria for Immunoglobulin Products
    • Suppliers and Commercial Supply Contracts
      • Fresh Blood Product Supply and Lifeblood
      • Plasma and Recombinant Product Supply
      • Imported Product Supply
      • Red Cell Diagnostic Product Supply
    • Australian Health Provider Access to Blood and Blood Products
    • Overseas Supply of Blood Products
  • Clinical Guidance
    • Clinical Guidance
      • Rh D Ig Guideline (Opens in a new tab/window)
      • PBM Guidelines (Opens in a new tab/window)
    • National Standards
    • Immunoglobulin
    • Patient Blood Management
      • Patient Blood Management (PBM) Resources
    • Transfusion-related Adverse Events
    • Bleeding Disorders
      • Australian Bleeding Disorders Registry (ABDR)
    • eLearning Courses
    • Public Consultations
    • Patient Blood Management Guidelines (Opens in a new tab/window)
  • Data and Research
    • Data and Research
    • Data and Reporting
    • Research Funding Program
      • Successful Grant Rounds
  • Patient Information
    • Patient information
      • Applying for overseas supply of blood products
    • Bleeding disorders
    • Blood disorders
    • Travelling with blood products
    • MyABDR app and the ABDR

Search

  • Donate Blood (Opens in a new tab/window)
  • About NBA
  • News and updates
  • Resources
  • BloodPortal login (Opens in a new tab/window)
  • Blood Products
    • Blood Products
    • National Product Price List
    • Fresh Blood Products
    • Albumin Products
    • Clotting Factor and Other Products
    • Immunoglobulin Products
      • Immunoglobulin Usage and Data
      • Intravenous Immunoglobulin (IVIg)
      • Subcutaneous Immunoglobulin (SCIg)
      • Normal Human Immunoglobulin (NHIg)
      • Hyperimmune Immunoglobulin Products
    • Access and Ordering
      • BloodSTAR for Ig Products
      • BloodSTAR Registration Form
      • BloodNet for Blood Products from Lifeblood
      • BloodNet System Interface
      • Frequently Asked Questions
    • Blood Product Management
      • Inventory Management
      • Blood Product Wastage
      • Blood and Inventory Management Resources
      • Case Studies
      • Single Unit Transfusion Guide
  • Supply System
    • Supply System
    • Managing Blood Supply
      • Risk Management
      • National Stewardship Program
      • Blood Product Labelling
    • Governance for Immunoglobulin Products
      • National Immunoglobulin Governance Committees
      • Criteria for Immunoglobulin Products
    • Suppliers and Commercial Supply Contracts
      • Fresh Blood Product Supply and Lifeblood
      • Plasma and Recombinant Product Supply
      • Imported Product Supply
      • Red Cell Diagnostic Product Supply
    • Australian Health Provider Access to Blood and Blood Products
    • Overseas Supply of Blood Products
  • Clinical Guidance
    • Clinical Guidance
      • Rh D Ig Guideline
      • PBM Guidelines
    • National Standards
    • Immunoglobulin
    • Patient Blood Management
      • Patient Blood Management (PBM) Resources
    • Transfusion-related Adverse Events
    • Bleeding Disorders
      • Australian Bleeding Disorders Registry (ABDR)
    • eLearning Courses
    • Public Consultations
    • Patient Blood Management Guidelines
  • Data and Research
    • Data and Research
    • Data and Reporting
    • Research Funding Program
      • Successful Grant Rounds
  • Patient Information
    • Patient information
      • Applying for overseas supply of blood products
    • Bleeding disorders
    • Blood disorders
    • Travelling with blood products
    • MyABDR app and the ABDR

Artificial Intelligence (AI) transparency statement

  • Home
  • Artificial Intelligence (AI) transparency statement

Our AI transparency statement explains how we intend to use AI technology, and how we will adopt and use AI in line with the Australian public's and Government's expectations.

The National Blood Authority’s (NBA) commitment to the safe and responsible use of AI supports our vision to save and improve Australian lives and patient outcomes through a world-class blood supply.

The Digital Transformation Agency’s (DTA) Policy for the responsible use of Artificial Intelligence (AI) in government(Opens in a new tab/window) sets a framework for the Australian Government’s safe, responsible, adoption and use of AI. Along with the Standard for AI transparency statements(Opens in a new tab/window) and Interim guidance on government use of public generative AI tools(Opens in a new tab/window).

Why we use AI

To achieve our vision to save and improve Australian lives and patient outcomes through a world-class blood supply in delivering better health and wellbeing for all Australians, the NBA commits to the safe and responsible adoption of AI to take advantage of the various benefits the technology provides. 

How we use AI

The NBA uses generative AI in line with the DTA’s Classification systems for use(Opens in a new tab/window) as below:

We use AI to enhance:

Analytics for insights 

Identifies, produces or understands insights within structured or unstructured materials via comprehensive data analysis, predictive modelling and/or reporting tools. 

Workplace productivity 

Automates routine tasks, manage workflows, and facilitate communication. 

We may apply AI in the following domains: 

DomainDescription
Service deliveryEnhances efficiency or accuracy of government services, by providing tailored and responsive services to the public and/or stakeholders.
Policy and legalAnalyses policies and legal documents to provide advice and assurance on their impact and supports policy development that is consistent with existing laws.
ScientificLeveraged in scientific endeavours to process complex datasets, simulate experiments, predict outcomes and enhance monitoring functions.
Corporate and enablingSupports corporate functions, including HR, finance, media and communications, and IT, by automating processes, optimising resource allocation and improving operational efficiency.

Our approach with AI

A human will assess all AI outputs to ensure accuracy. We will not use AI for decision making purposes.

The NBA isn’t using AI applications where the public can directly interact with or be impacted by AI. We will update this transparency statement if our approach changes. 

Our commitment

The NBA is committed to using AI in a responsible and transparent way. Our AI initiatives will align with the APS values and have the publics’ best interest at heart. We will continue to work closely with the DTA and use AI in accordance with applicable:

  • legislation
  • regulations
  • frameworks
  • policies
  • best practice. 

Safe and responsible AI adoption

We will be transparent as we adopt responsibly the evolving AI technology and policy requirements. 

These will align with the DTA’s Policy, advice and guidance on the safe, responsible and ethical use of AI.

We will leverage whole of Australian Government policies and develop internal policies and guidance materials when necessary for:

  • AI Governance and approval processes
  • acceptable use of AI in the NBA
  • ethical considerations
  • Freedom of Information (FOI) considerations
  • record keeping
  • security, procurement of AI systems
  • risk mitigation and technical guardrails
  • roles and responsibilities when using AI and required training for identified roles. 

These internal policies will apply to all employees (including contractors) and consultants.

We will update this transparency statement as the NBA continues to develop policies on AI usage and to implement AI technology. 

AI systems we use

What we useHow we useCommenced
GovAI Multi-ModelWe use the GovAI platform as a secure space for staff to test AI models and to support staff learning. January 2026
Microsoft 365 CopilotWe use Microsoft 365 Copilot within the NBA controlled environment.February 2026
Microsoft Copilot via GovTEAMSWe use Microsoft Copilot in the secure GovTEAMS environment.January 2026
GitHubWe use GitHub Copilot for software development.February 2026

Privacy notice for Microsoft Teams recordings and transcripts

Click here to find out how we manage the personal information we collect about you when you attend an MS Teams meeting that we record and transcribe.

Contact 

The Chief Information Officer is our AI Accountable Official for the NBA. 

For questions about this statement or the NBA’s use of AI, you can email ai@blood.gov.au or see the details on the contact us page of the NBA website.

 

Last updated: 13 Feb 2026

Back to top

The National Blood Authority acknowledges the Traditional Owners and Custodians of Country throughout Australia, and their continuing connection to land, water and community. We pay our respects to the people, the cultures and the elders past, present and emerging.

National Blood Authority

  • About the NBA
  • Work with us
  • Contact Us
  • Data and reporting
  • Freedom of information
  • Public interest disclosure
  • Resources
  • Accessibility
  • Privacy
  • Copyright
  • Disclaimer
  • BloodPortal Terms and Conditions of Use

Information

  • Blood Products
  • Managing blood supply
  • Supply systems
  • Clinical guidance
  • Patient information
  • Data and research
  • Website feedback